Generic placeholder image

Recent Patents on Endocrine, Metabolic & Immune Drug Discovery


ISSN (Print): 1872-2148
ISSN (Online): 2212-3334

Update on ICOS: A Possible Target for Turning-Off Autoimmunity

Author(s): Priya Sakthivel

Volume 3, Issue 3, 2009

Page: [205 - 213] Pages: 9

DOI: 10.2174/187221409789104755

Price: $65


Inducible Co-stimulator (ICOS) is one of the co-stimulatory molecules that are unregulated within hours after TCR engagement. The interaction between ICOS and its ligand ICOSL positively co-stimulates T cell activation and proliferation. Thus, ICOS/ICOSL pathway contributes to one of the predisposing factors for autoimmune condition. Therefore, the positive co-stimulatory properties of ICOS are now being regarded as a possible and potential target for treating autoimmune disorders. Several in vivo studies have confirmed the amelioration of autoimmune disease by targeting ICOS pathway. This mini-review comprehensively describes the updated issues regarding ICOS from their discovery and functional consequences (at both genetic and protein aspects) to the recent patents in targeting ICOS pathway for turning-off immune responses in autoimmunity.

Keywords: ICOS, ICOSL (B7RP-1), co-stimulatory molecules, autoimmune disease

Rights & Permissions Print Cite
© 2024 Bentham Science Publishers | Privacy Policy